Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring
E Jabbour, H Kantarjian - American journal of hematology, 2016 - Wiley Online Library
Disease overview: Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm with
an incidence of 1‐2 cases per 100,000 adults. It accounts for approximately 15% of newly …
an incidence of 1‐2 cases per 100,000 adults. It accounts for approximately 15% of newly …
Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring
E Jabbour, H Kantarjian - American journal of hematology, 2018 - Wiley Online Library
Disease overview Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …
Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management
E Jabbour, H Kantarjian - American journal of hematology, 2014 - Wiley Online Library
Disease overview: Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm with
an incidence of 1–2 cases per 100,000 adults, and accounts for∼ 15% of newly diagnosed …
an incidence of 1–2 cases per 100,000 adults, and accounts for∼ 15% of newly diagnosed …
Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management
E Jabbour, H Kantarjian - American journal of hematology, 2012 - Wiley Online Library
Abstract Disease overview: Chronic Myeloid Leukemia (CML) is a myeloproliferative
neoplasm with an incidence of one–two cases per 100,000 adults and accounts for∼ 15 …
neoplasm with an incidence of one–two cases per 100,000 adults and accounts for∼ 15 …
Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring
E Jabbour, H Kantarjian - American journal of hematology, 2020 - Wiley Online Library
Disease overview Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …
Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring
E Jabbour, H Kantarjian - American journal of hematology, 2022 - Wiley Online Library
Abstract Disease Overview Chronic Myeloid Leukemia (CML) is a myeloproliferative
neoplasm with an incidence of 1–2 cases per 100 000 adults. It accounts for approximately …
neoplasm with an incidence of 1–2 cases per 100 000 adults. It accounts for approximately …
Management of chronic myeloid leukemia in 2023–common ground and common sense
J Senapati, K Sasaki, GC Issa, JH Lipton… - Blood cancer …, 2023 - nature.com
With the improving knowledge of CML and its management, the goals of therapy need to be
revisited to ensure an optimal use of the BCR:: ABL1 TKIs in the frontline and later-line …
revisited to ensure an optimal use of the BCR:: ABL1 TKIs in the frontline and later-line …
Use of second-and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm
E Jabbour, H Kantarjian, J Cortes - Clinical Lymphoma Myeloma and …, 2015 - Elsevier
Although imatinib remains the gold standard for first-line treatment of chronic myeloid
leukemia (CML), increasing recognition of imatinib resistance and intolerance has led to the …
leukemia (CML), increasing recognition of imatinib resistance and intolerance has led to the …
Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions
AEG Osman, MW Deininger - Blood reviews, 2021 - Elsevier
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by a reciprocal
translocation [t (9; 22)(q34; q11. 2)] that leads to the fusion of ABL1 gene sequences (9q34) …
translocation [t (9; 22)(q34; q11. 2)] that leads to the fusion of ABL1 gene sequences (9q34) …
A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase
V García-Gutiérrez, M Breccia, E Jabbour… - Journal of Hematology & …, 2022 - Springer
Tyrosine kinase inhibitors (TKIs) have vastly improved long-term outcomes for patients with
chronic myeloid leukemia (CML). After imatinib (a first-generation TKI), second-and third …
chronic myeloid leukemia (CML). After imatinib (a first-generation TKI), second-and third …